News

Bionique Receives Asahi Kasei Bioprocess Division Award

We’re excited to announce that the Bionique team has received the 2023 Asahi Kasei Bioprocess Division Award. This award recognizes innovation and outstanding achievement. Congratulations to Kevin Susice, Eric Damour, Brandy VanBuskirk, and Doug Crowell for their remarkable contributions to introducing automation in testing!

Bionique to Expand After Acquisition by Asahi Kasei Medical

On December 15, 2021, Bionique announced it has been acquired by a subsidiary of Japan-based healthcare pioneer Asahi Kasei Medical Co., Ltd. Bionique joins Austria-based viral and prion safety testing services expert ViruSure GmbH as part of the global biosafety testing services unit of Asahi Kasei Medical’s Bioprocess Division. Both Bionique and ViruSure will continue operations under their existing, widely respected brands.

Bionique in Association with ThermoFisher and American Pharmaceutical Review Present: Key Considerations for Implementing Rapid Microbial Methods for Mycoplasma Detection.

This white paper explains the importance of demonstrating product-specific suitability, defining representative sample, consistent sampling protocols, accommodating volume and turnaround time constraints, and the need to establish equivalence. Rapid microbial methods are increasingly being used by cell therapy developers motivated by particularly short production schedules and product shelf life, and has grown to include raw material providers interested in reducing inventory hold times.

Bionique Appoints Gladis Zamparo as new Chief Executive Officer

Bionique Testing Laboratories, Inc. is thrilled to announce that it has selected Gladis Zamparo as its next CEO effective November 16, 2020. Zamparo has spent two decades in global organizations driving change through innovative solutions, operational excellence and financial rigor.

Bionique’s Research Presented in Advances in Biotechnology & Microbiology

Research conducted at Bionique Testing Laboratories was published in an article that studies the impact of aerobicity on colony growth of various mollicutes, including mycoplasma, on agar in order to confirm the optimal oxygen content for colony growth for isolation of mycoplasma from cell cultures for routine subcultivation. The purpose of the study was to continue to be an industry leader and address a lack of information pertaining to the impact of atmospheric testing conditions, aerobic or anaerobic, compared to the industries common standards and good practices.